...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Revista Brasileira de Ginecologia e Obstetrícia >Impacts of Cytochrome P450 2D6 (CYP2D6) Genetic Polymorphism in Tamoxifen Therapy for Breast Cancer Impactos do polimorfismo genético do citocromo P450 2D6 (CYP2D6) na terapia com tamoxifeno para cancer de mama
【24h】

Impacts of Cytochrome P450 2D6 (CYP2D6) Genetic Polymorphism in Tamoxifen Therapy for Breast Cancer Impactos do polimorfismo genético do citocromo P450 2D6 (CYP2D6) na terapia com tamoxifeno para cancer de mama

机译：细胞色素P450 2D6（CYP2D6）遗传多态性在他莫昔芬治疗乳腺癌中的影响细胞色素P450 2D6（CYP2D6）遗传多态性在他莫昔芬治疗乳腺癌中的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Tamoxifen (TMX) is the main drug used both in pre and postmenopausal women as adjuvant treatment for hormone receptor-positive breast cancer. An important barrier to the use of TMXis the development ofdrug resistance causedby molecular processes related to genetic and epigenetic mechanisms, such as the actions of cytochrome P450 2D6 (CYP2D6) polymorphisms and of its metabolites. The present study aimed to review recent findings related to the impact of CYP2D6 polymorphisms and how they can affect the results of TMX in breast cancer treatment. The keywords CYP2D6, tamoxifen, and breast cancer were searched in the PubMed, Scopus, The Cochrane Library, Scielo, and Bireme databases. Studies related to other types of neoplasms or based on other isoenzymes from cytochrome P450, but not on CYP2D6, were excluded. The impact of CYP2D6 polymorphisms in the TMX resistance mechanism remains unclear. The CYP2D6 gene seems to contribute to decreasing the efficacy of TMX, while the main mechanism responsible for therapy failure, morbidity, and mortality is the progression of the disease.
机译：他莫昔芬（TMX）是绝经前和绝经后妇女的主要药物，可作为激素受体阳性乳腺癌的辅助治疗。使用TMX的一个重要障碍是由与遗传和表观遗传机制相关的分子过程引起的耐药性的发展，例如细胞色素P450 2D6（CYP2D6）多态性及其代谢产物的作用。本研究旨在回顾与CYP2D6多态性的影响有关的最新发现，以及它们如何影响TMX在乳腺癌治疗中的结果。在PubMed，Scopus，Cochrane Library，Scielo和Bireme数据库中搜索了CYP2D6，他莫昔芬和乳腺癌这些关键词。排除与其他类型肿瘤相关或基于细胞色素P450的其他同工酶的研究，但不基于CYP2D6的研究。 CYP2D6多态性对TMX耐药机制的影响尚不清楚。 CYP2D6基因似乎有助于降低TMX的疗效，而导致治疗失败，发病率和死亡率的主要机制是疾病的进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号